Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)
- 21:00 - 23:59
- 8/06/2022
- Location: On-Demand
- Not for CME Credit
- Type: Workshop
- Track: N/A
- Moderators:Yi-Long Wu, Chunxue Bai, Caicun Zhou, Karen Kelly
-
+
WS08.12 - Discussant for Oral Abstracts
23:00 - 23:20 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading...
-
+
EP01.06 - Early Detection and Screening - Risk Stratification
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Early Detection and Screening - Risk Stratification
-
+
EP01.06-003 - Female Asian Nonsmoker Screening Study (FANSS): Exploring Lung Cancer Screening in a High Risk Population
Presenter: Elaine Shum- Abstract
Loading... -
+
EP01.06-008 - Low Dose CT Screening in Asian Female-Never-Smokers is as Efficacious as in Asian Male-Ever-Smokers. A Systemic Review and Meta-Analysis
Presenter: Natthaya Triphuridet- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Presenter: Alexander Drilon- Abstract
Loading... -
+
EP08.02-118 - TRUST-II: A Global Phase II Study for Taletrectinib inROS1fusion Positive Lung Cancer and Other Solid Tumors
Presenter: Misako Nagasaka- Abstract
Loading...
-
+
MA07 - Overcoming Resistance to EGFR Inhibitors
- 12:15 - 13:15
- 8/08/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Dana Lucia Stanculeanu, Ross Soo
-
+
MA07.04 - Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
12:22 - 12:27 | Presenter: Melina Elpi Marmarelis
- Abstract
Loading... -
+
MA07.09 - BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study
12:52 - 12:57 | Presenter: Sun Min Lim
- Abstract
Loading...
-
+
MA13 - Update on ROS1 Inhibitors and New Pathways
- 12:00 - 13:00
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Moderators:Lorenza Landi, Jii Bum (Joy) Lee
-
+
MA13.03 - Integrated Efficacy and Safety of Brigatinib Following Alectinib Treatment in the ALTA-2 and J-ALTA Studies
12:02 - 12:07 | Presenter: Sai-Hong Ignatius Ou
- Abstract
Loading...